FDA enforcement against compounded tirzepatide: the 2026 record
Every dated FDA action against compounded GLP-1 marketing, the adverse-event figure almost every site gets wrong, the tirzepatide-B12 adduct, counterfeit vials naming pharmacies that do not exist, and the ruling that affordability is not a clinical need.
The enforcement record
FDA enforcement: the 2025–2026 record
| Date | Action | What FDA said |
|---|---|---|
| 16 Sep 2025 | 55+ warning letters to online sellers of compounded GLP-1s. | Misleading direct-to-consumer advertising. The first wave. |
| 16 Jan 2026 | Warning letter to Boothwyn Pharmacy LLC (a 503A pharmacy). Published 10 Feb 2026. | Insanitary conditions, and non-compliance with the products' stated strength, quality or purity. This is not a marketing complaint — it is a manufacturing one. |
| 5 Feb 2026 | TrumpRx launches — direct FDA-approved GLP-1 access. | Semaglutide tablets $149–$299; semaglutide injections $199–$349; tirzepatide injections $299–$449 — against list prices of $1,349 and $1,087. |
| 6 Feb 2026 | FDA announces it will restrict GLP-1 active pharmaceutical ingredients used in non-approved compounded products, and act against misleading DTC advertising. | Press release: FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. |
| 9 Feb 2026 | Novo Nordisk sues Hims & Hers for patent infringement. | Manufacturer litigation, not just agency enforcement. |
| 3 Mar 2026 | 30 warning letters to telehealth companies marketing compounded GLP-1s. | Marketing implies equivalence to FDA-approved products, and branding obscures the actual compounder. |
| 30 Apr 2026 | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List. Federal Register docket 2026-08552. | No clinical need. And critically: FDA explicitly rejects affordability and insurance access as constituting clinical need. |
| 21 May 2026 | FDA reports 1,700+ adverse events for compounded GLP-1s. | Up from 775 in February 2025. |
| Mid-Jun 2026 | Third tranche: 25 more warning letters. | The mid-2026 lull was temporary. FDA releases letters in coordinated batches, so a quiet period is not reduced priority. |
In the 30 April 2026 Federal Register notice (docket 2026-08552), the agency stated that there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk — and went out of its way to clarify that supply and affordability are not what the statute means by clinical need.
In plain terms: there are FDA-approved products; they work; patients can be treated with them. Whether a patient can afford them is a different problem, with a different set of policy tools.
That single sentence does enormous work. Every compounded-GLP-1 marketing page in America is, at bottom, an affordability argument. The agency has now said, on the record, that affordability is not a legal basis for compounding these drugs. If you are choosing a compounded programme because it is cheaper, you should know that the regulator has explicitly said that reason does not count.
Adverse events: the number almost every site gets wrong
Source: FDA GLP-1 webpage, reporting 1,700+ adverse events associated with compounded semaglutide and tirzepatide as of May 21, 2026 — against the 775 total, Feb 2025 figures from February 2025 that almost every comparison site is still quoting. Reports are voluntary and do not establish causation, but the trend is the point.
As of 21 May 2026, the FDA reports having received more than 1,700 adverse events associated with compounded semaglutide and tirzepatide. That is more than double the figure still in circulation, in roughly fifteen months.
Adverse-event reports are voluntary, are not adjudicated, and do not by themselves establish causation. That caveat is real and we will not drop it. But a site that quotes the 2025 number in mid-2026 is not being cautious — it is being out of date, and in a direction that flatters the product it is paid to sell.
The tirzepatide–B12 adduct
This matters far beyond one study, because it exposes the flaw in the whole ‘personalized dosing’ defence. Adding B12 was one of the commonest ways compounders argued their product was not “essentially a copy” of the approved drug — a clinical difference that kept them inside the law. The finding shows that the additive did not merely differentiate the product on paper. It chemically changed it, into something nobody has tested in a human being.
What to do: if you are taking a compounded tirzepatide that contains B12 — and many do, often marketed as ‘tirzepatide + B12’ or ‘with methylcobalamin’ — ask your provider and your pharmacy, in writing, whether they have tested for adduct formation. Most will not have. That answer is itself information.
Counterfeits, APIs and substances that cannot be compounded
This is why ‘the pharmacy is named on the label’ is not, by itself, verification. The name on the vial has to be a pharmacy you can look up in a state board database. If you cannot find it, you have not found a discreet pharmacy; you may have found a fabricated one.
The agency has also issued import alerts to keep GLP-1 active pharmaceutical ingredients with quality concerns out of the country, and operates a ‘green list’ approach to acceptable API sources. Ask your provider where its API comes from. Most will not know, which is itself the answer.
If a provider offers you retatrutide, cagrilintide, or any ‘next-generation’ peptide that is not an approved drug, that provider is either unaware of the FDA's position or is disregarding it. Either way, it tells you what you need to know about everything else they sell you.
The same applies to semaglutide salts (sodium, acetate), which the FDA has separately stated are not the same active ingredient as approved semaglutide and are not appropriate for compounding.
The brand channels — now four of them
• Semaglutide tablets: $149–$299/month (list price $1,349)
• Semaglutide injections: $199–$349/month (list price $1,349)
• Tirzepatide injections: $299–$449/month (list price $1,087)
This is a fourth manufacturer-adjacent channel, alongside LillyDirect, NovoCare and the retail pharmacy route — and it prices in the same band. The practical point is unchanged and getting stronger: before you buy any GLP-1 through a telehealth platform, price the FDA-approved product first. There are now four ways to do that, and the cheapest of them undercuts most of the compounded market.
What all of this actually means for you
Read together, the 2025–2026 record says something specific, and it is not what the marketing says.
1. The legal basis is gone, and the FDA has closed the escape route. The shortage exception ended. The courts upheld it. The 503B bulks route is being closed. And the agency has now rejected affordability — the only argument the industry actually has — as a legal basis for compounding these drugs.
2. The safety signal is growing, not shrinking. Adverse-event reports have more than doubled since the figure most sites still quote. A 503A pharmacy has been cited for insanitary conditions and for products that did not match their stated strength, quality or purity. Counterfeit vials bear the names of pharmacies that do not exist.
3. The “personalized dosing” defence is chemically as well as legally weak. Adding B12 was a common way to argue a product was not a copy. A March 2026 study found that it forms a tirzepatide–B12 adduct that does not exist in the approved drug and has never been tested in humans.
4. Meanwhile the brand got cheap. LillyDirect, NovoCare and now TrumpRx all price FDA-approved GLP-1s in the $149–$449 band. The gap that justified the regulatory and safety risk has largely closed.
We are a publication with commercial relationships with providers in this market, and we are telling you this anyway, because it is what the evidence says. Price the FDA-approved product first. If a compounded programme still makes sense for you afterwards, at least you will have chosen it with the facts.
How this works in practice
A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.
Every price carries a status. Verified means we hold a dated capture of the provider's own page. Reported — pending verification means a provider or third party reports it and we have not captured it ourselves. Evaluation in progress means we are not asserting it. We do not upgrade a price to Verified because a comparison site published it — sites in this category contradict each other routinely, and a number repeated by three affiliate blogs is still one unverified number.
Every medical claim traces to a primary source. FDA labels and guidance for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy — they may be described as anecdotal sentiment, labelled as such. Animal research is never presented as proof of a human clinical effect.
Every ranking shows its arithmetic. Where a provider we have a commercial relationship with ranks well, the calculation that produced that result is printed on the page. If the arithmetic is wrong, you can see that it is wrong, and tell us.
Commercial relationships and what they do not buy
The publisher and certain principals have financial relationships with some of the telehealth providers listed on this site, and we may earn a commission when readers use certain links. That is how this publication is funded, and we state it in the footer of every page rather than burying it.
What compensation does not do: it does not change a score, a rank, an inclusion decision, or a negative finding. Providers cannot pay for placement, cannot suppress an accurate criticism, and cannot review their own page before publication. Where a commercially-related provider loses a category, we say so — a comparison in which one provider wins everything is an advertisement, and the fastest way to tell the difference is to look for the losses.
Corrections
We publish prices in a market that changes them frequently, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Both readers and providers can submit corrections with evidence, through the same process and to the same standard.
Our own record so far includes removing a set of provider prices we had sourced from a third-party comparison site and could not substantiate, and correcting brand-pricing figures that had gone stale after a manufacturer price cut. Both corrections made the site less flattering to conclusions we had already published. That is the point.